NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Cumberland Pharmaceuticals Inc. (CPIX) Stock Analysis

Cumberland Pharmaceuticals Inc. (CPIX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CPIX

$8.17

+$0.21 (+2.64%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CPIX with… →

CPIX Key Statistics

As of Oct 21, 2026
Trading
Open
$7.81
Previous Close
$7.96
Day's Range
7.81–8.73
52-Week Range
1.85–9.28
Volume
141.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.04
Valuation
Market Cap
$122.41M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
58.36
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.76
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.62
Financials (FY)
Revenue (FY)
$44.52M+17.57%
Net Income (FY)
−$2.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
−24.64%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.98M
1-Year Return
+189.45%
Dividend and dates
Ex-Dividend Date
August 3, 2026
Earnings Date
November 3, 2026
Avg Volume
75.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CPIX closed at $8.17, +189.45% over 1 year.

Cumberland Pharmaceuticals Inc. (CPIX) has a market capitalization of $122.41M.

In fiscal 2025, CPIX reported revenue of $44.52M.

CPIX Stock Return by Calendar Year

Cumberland Pharmaceuticals Inc. (CPIX) 10-year return: what $10,000 became

1 year
$10,000 $28,945
+189.45%
5 years
$10,000 $39,461
+294.61%
10 years
$10,000 $21,371
+113.71%

If you had invested $10,000 in Cumberland Pharmaceuticals Inc. (CPIX) 10 years ago, at the close on October 21, 2016, it would have been worth $21,371 at the close on October 21, 2026: +113.71% in total, +7.89% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+164.72%
2025+67.93%
2024+32.40%
2023−20.44%
2022−51.82%
2021+58.30%
2020−42.72%
2019−14.59%
2018−18.07%
2017+33.82%
2016 (partial year)+19.05%

As of October 21, 2026.

CPIX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$44.52M−$2.84M−6.4%
2024$37.87M−$6.48M−17.1%
2023$39.55M−$6.28M−15.9%
2022$42.01M−$5.57M−13.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$44.52M$37.85M−$2.79M−$2.84M−6.4%
2024$37.87M$31.28M−$6.43M−$6.48M−17.1%
2023$39.55M$33.49M−$9.55M−$6.28M−15.9%
2022$42.01M$32.89M−$5.70M−$5.57M−13.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CPIX Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricCPIXDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.762.1032% above
Profit margin−24.64%−8.14%16.5 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cumberland Pharmaceuticals Inc. (CPIX) is capitalised at $122.41M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 88 employees.

The 52-week range on file runs from $1.85 to $9.28. CPIX last closed at $8.17 on October 21, 2026. That is +$0.21 (+2.64%) against the previous close. The latest close sits 341.62% above that 52-week low.

Financial Health

In fiscal 2025, Cumberland Pharmaceuticals Inc. reported revenue of $44.52M. Against the prior fiscal year total of $37.87M, that is a change of +17.57%. The same year closed with a net loss of $2.84M. The reported profit margin is −24.64%. That is 16.5 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.62.

Across the 4 fiscal years on file, revenue moves from $42.01M in 2022 to $44.52M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 58.36. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.67. The price-to-sales ratio is 2.76. On price-to-sales that is 31.57% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is +189.45%. Measured over 10 years, that is +7.89% a year compounded. Beta against the wider market is reported at 0.04. Annualized volatility over the trailing 10 years is 88.58%.

Growth & Income

The latest dividend on file for CPIX dates from 2026.

So far in 2026 the total return is +164.72%. The strongest complete calendar year on file is 2025 at +67.93%; the weakest is 2022 at −51.82%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Cumberland Pharmaceuticals Inc. (CPIX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cumberland Pharmaceuticals Inc. CPIX $122.41M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Cumberland Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Visit website →